In multiple cancer types, including breast cancer, PIK3CA is considered oncogenic, mutations of the alpha catalytic subunit of PI3K having an incidence of 40% in ER+/HER2− primary and metastatic tumors. Here, ESR1 is linked to breast carcinoma.